ArticleImmunology2019
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.
Article in Immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Sustained microparticle-mediated intracellular immunomodulation enhances tolerogenic dendritic cell stability and antigen-specific Treg induction.Frontiers in immunology · 2026Article
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- Dendritic Cell-Based Therapeutic Immunization Induces Th1/Th17 Responses and Reduces Fungal Burden in Experimental Sporotrichosis.Microorganisms · 2025Article
- Immune cells in systemic lupus erythematosus: biology and traditional Chinese medicine therapy.Acta pharmacologica Sinica · 2025Review
- Regulatory cell therapy for kidney transplantation and autoimmune kidney diseases.Pediatric nephrology (Berlin, Germany) · 2025Review
- Cell-Based Therapeutic Strategies for Autoimmune Diseases.ImmunoTargets and therapy · 2025Review
- Dexamethasone loaded DNA scavenger nanogel for systemic lupus erythematosus treatment.Bioactive materials · 2025Article
- Outgrowth of Escherichia is susceptible to aggravation of systemic lupus erythematosus.Arthritis research & therapy · 2024Article
- Current cell therapies for systemic lupus erythematosus.Stem cells translational medicine · 2024Review
- Ex Vivo-Generated Tolerogenic Dendritic Cells: Hope for a Definitive Therapy of Autoimmune Diseases.Current issues in molecular biology · 2024Review
- A comprehensive overview of tolerogenic vaccine adjuvants and their modes of action.Frontiers in immunology · 2024Review
- Heme catabolism and heme oxygenase-1-expressing myeloid cells in pathophysiology.Frontiers in immunology · 2024Review
- Helios as a Potential Biomarker in Systemic Lupus Erythematosus and New Therapies Based on Immunosuppressive Cells.International journal of molecular sciences · 2023Review
- Nanomaterials for antigen-specific immune tolerance therapy.Drug delivery and translational research · 2023Review
- Significant improvement of systemic lupus erythematosus manifestation in children after autologous dendritic cell transfer: a case report and review of literature.Therapeutic advances in vaccines and immunotherapy · 2023Article
- The Role of Heme Oxygenase-1 as an Immunomodulator in Kidney Disease.Antioxidants (Basel, Switzerland) · 2022Review
- Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Trained Immunity Contribution to Autoimmune and Inflammatory Disorders.Frontiers in immunology · 2022Review
- Contribution of Dysregulated DNA Methylation to Autoimmunity.International journal of molecular sciences · 2021Review
- A specialist antigen storage compartment in dendritic cells to sustain cross-presentation.Immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current treatments for systemic autoimmune diseases partially improve the health of patients displaying low pharmacological efficacy and systemic immunosuppression. Here, the therapeutic potential of transferring tolerogenic dendritic cells (tolDCs) generated with heme-oxygenase inductor cobalt (III) protoporphyrin IX (CoPP), dexamethasone and rosiglitazone for the treatment of systemic autoimmunity was evaluated in two murine models of systemic lupus erythematosus (SLE), MRL-Fas
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.